Weight Loss Meds
Ozempic vs Wegovy: What’s the difference between them?
29
Mar
Mar
Ozempic vs Wegovy: What’s the difference between them?, Ozempic and Wegovy are the two brand names that Novo Nordisk uses to market injectable semaglutide.
Ozempic is used to treat type 2 diabetes and prevent major cardiovascular problems in certain patients, while Wegovy is used for chronic weight management and helps with weight loss.
The table below outlines the specific conditions that Ozempic and Wegovy are used to treat and the dosage forms and strengths each semaglutide-containing product comes in.
| Ozempic | Wegovy | |
| Generic name | Semaglutide | Semaglutide |
| Marketed by | Novo Nordisk | Novo Nordisk |
| Dosage form and strength | Injection – 2mg/1.5ml (1.34mg/ml)Single-patient-use pens (delivering 0.25mg or 0.5mg, or 1mg per injection)Single-patient-use pen (delivering 1mg per injection)Injection – 4 mg/3ml (1.34mg/ml)Injection – 8 mg/3ml (2.68mg/ml)Single-patient-use pen (delivering 2mg per injection)Dose is increased slowly up to a maximum of 2mg weekly if required | Injection – pre-filled, single-dose pen delivering doses of 0.25, 0.5, 1.7 or 2.4mg). The dose is increased slowly until a maintenance dose of 2.4mg weekly is reached |
| Uses | As an add-on to diet and exercise to improve glycemic control in adults with type 2 diabetes to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease | An add-on to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:30kg/m2 or greater (obesity) or27kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition, such as high blood pressure, type 2 diabetes and dyslipidemia As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity). |
| First approved in US | 2017 | 2021 |
